Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib plus capecitabine vs placebo plus capecitabine in second-line biliary tract cancer
2017-000114-30Phase 2Terminated
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in biliary cancer comparing Varlitinib plus capecitabine with Placebo plus capecitabine (2 arms). Primary endpoint: Safety lead-in (primary). Started Sep 2017; status: terminated.
02
Drugs
varlitinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2017-000114-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000114-30.